Kringle Pharma, Inc. (4884.T)
- Previous Close
816.00 - Open
813.00 - Bid 810.00 x --
- Ask 820.00 x --
- Day's Range
804.00 - 821.00 - 52 Week Range
527.00 - 1,328.00 - Volume
37,700 - Avg. Volume
110,956 - Market Cap (intraday)
5.53B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-118.23 - Earnings Date May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
www.kringle-pharma.comRecent News: 4884.T
View MorePerformance Overview: 4884.T
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4884.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4884.T
View MoreValuation Measures
Market Cap
5.53B
Enterprise Value
3.22B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
69.09
Price/Book (mrq)
2.62
Enterprise Value/Revenue
40.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.95%
Return on Equity (ttm)
-37.52%
Revenue (ttm)
79.51M
Net Income Avi to Common (ttm)
-799.65M
Diluted EPS (ttm)
-118.23
Balance Sheet and Cash Flow
Total Cash (mrq)
2.1B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--